Ahmad Sufian Ab Rahman, Consultant Medical Oncologist, Internal Medicine Physician, Clinician Researcher at Aurelius Hospital Negeri Sembilan, shared on LinkedIn:
“Bridging Gaps in Global Oncology: The Launch of OncoTrials MY as an Advanced, AI-Digital Platform for Cancer Clinical Trial Access and Therapy Matching in Malaysia
As part of the ongoing global efforts to bridge the gaps in various aspects of the cancer ecosystem, digital innovation continues to land meaningful solutions. OncoTrials MY, a transformative AI-digital platform initiative founded by Dr. Ahmad Sufian Ab Rahman was meticulously designed to facilitate and streamline the search, matching, and access to cancer clinical trials across Malaysia with speed and a seamless end-to-end process. By bridging how patients, clinicians, researchers, Contract Research Organizations (CROs), and industry sponsors navigate the landscape of oncology, the platform redefines modern trial navigation.
Core Functions and Capabilities
Built to address longstanding bottlenecks in oncology research and patient navigation, OncoTrials MY delivers a robust suite of targeted capabilities designed to connect stakeholders and optimize the clinical trial ecosystem:
- Intelligent Clinical Trial Matching: The platform functions as a centralized hub that matches cancer patients with appropriate clinical trials, bridging the gap between individuals seeking advanced therapeutic options and active research studies.
- Geographic & Epidemiological Insights: Provides a broad, comprehensive view of cancer incidence patterns alongside the geographic distribution and availability of cancer clinical trials across Malaysia, empowering stakeholders with crucial data visibility.
- Streamlined Patient Accrual: By optimizing the screening and recruitment pipeline, OncoTrials MY helps principal investigators, CROs, and sponsors accelerate trial enrollment, reducing delays in cancer drug development and clinical evaluation.
- Precision Oncology Integration: The platform facilitates care alignment based on individual patient molecular profiles and mutation statuses, supporting targeted therapeutic strategies.
- Multi-Stakeholder Collaboration: It serves as a unified digital infrastructure bringing together patients, treating physicians, clinical investigators, and industry sponsors to foster a cohesive environment for oncology advancement.
- Oncologist-backed Concierge: The platform is supported by oncology specialists with good experience in the design, and conduct of early and late phase cancer clinical trials, providing strong oversight to the intended functions of the platform and outcomes it intends to deliver to the users.
Vision for the Future
At its core, OncoTrials MY is driven by a transformative vision: to enhance and improve survival outcomes for cancer patients by dramatically increasing access to cutting-edge cancer clinical trials. By uniting multidisciplinary stakeholders to streamline therapy development and personalize care pathways, OncoTrials MY positions itself not only as a localized solution, but as a meaningful contributor to addressing the systemic gaps inherent in global oncology.”
Other posts featuring Ahmad Sufian Ab Rahman on OncoDaily.